Australia's most trusted
source of pharma news
Tuesday, 08 July 2025
Posted 4 July 2025 AM
Five new drugs targeting rare diseases plus new indications across oncology and cardiology will likely be filed with the TGA by the end of the year, if not sooner – and one candidate comes with a hefty price tag.
Last month, Australia’s medicines regulator handed orphan drug designations to a handful of innovative medicines, including Chiesi’s Myalept, a recombinant form of human leptin for the treatment of lipodystrophy.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.